The Use of Allostem in Subtalar Fusions

Coetzee, J. N.; Myerson, Mark S.; Anderson, John G.

doi:10.1016/j.fcl.2016.07.011

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro cultured ASCs have been widely used in orthopedics, especially in the process of production of various biomaterials, grafts, and scaffolds [118][119][120][121]. To date, there have been few clinical trials that have focused on using ASCs in standard treatment.…”

Section: Human Clinical Trialsmentioning

confidence: 99%

“…Adipose-derived stem cells have also been used in the process of allograft preparation. The clinical utility of ASC allografts was tested in patients with subtalar joint arthritis as an alternative treatment to typical autologous bone graft in performed subtalar arthrodesis and both methods had similar efficacy in patients' quality of life enhancement [121,125]. Furthermore, it has been reported that the intradiscal injection of a mixture of ASCs and hyaluronic acid was safe for patients and could significantly reduce chronic discogenic low back pain [126].…”

Section: Human Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Cultures of Adipose-Derived Stem Cells: An Overview of Methods, Molecular Analyses, and Clinical Applications

Jankowski

Dompe

Sibiak

et al. 2020

Cells

View full text Add to dashboard Cite

Adipose-derived stem cells (ASCs) exhibiting mesenchymal stem cell (MSC) characteristics, have been extensively studied in recent years. Because they have been shown to differentiate into lineages such as osteogenic, chondrogenic, neurogenic or myogenic, the focus of most of the current research concerns either their potential to replace bone marrow as a readily available and abundant source of MSCs, or to employ them in regenerative and reconstructive medicine. There is close to consensus regarding the methodology used for ASC isolation and culture, whereas a number of molecular analyses implicates them in potential therapies of a number of pathologies. When it comes to clinical application, there is a range of examples of animal trials and clinical studies employing ASCs, further emphasizing the advancement of studies leading to their more widespread use. Nevertheless, in vitro studies will most likely continue to play a significant role in ASC studies, both providing the molecular knowledge of their ex vivo properties and possibly serving as an important step in purification and application of those cells in a clinical setting. Therefore, it is important to consider current methods of ASC isolation, culture, and processing. Furthermore, molecular analyses and cell surface properties of ASCs are essential for animal studies, clinical studies, and therapeutic applications of the MSC properties.

show abstract

Section: Human Clinical Trialsmentioning

confidence: 99%

Section: Human Clinical Trialsmentioning

confidence: 99%

In Vitro Cultures of Adipose-Derived Stem Cells: An Overview of Methods, Molecular Analyses, and Clinical Applications

Jankowski

Dompe

Sibiak

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Injection/infusion buffers were fairly well reported (91%) and predominately consisted of Plasma-Lyte, Plasma-Lyte A, Lactated Ringer’s solution, and saline with or without human serum albumin (HSA) or dimethylsulfoxide (DMSO) at varying concentrations ( Table 1 ). Buffer solution was not used in an AD MSC bone allograft device in arthrodesis surgery ( Coetzee et al, 2016 ; Myerson et al, 2019 ). One publication reported intradiscal injection of non-expanded BM concentrate ( Pettine et al, 2015 ).…”

Section: Resultsmentioning

confidence: 99%

From Vial to Vein: Crucial Gaps in Mesenchymal Stromal Cell Clinical Trial Reporting

Wiese

Wood

Braid

2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Retrospective analysis of clinical trial outcomes is a vital exercise to facilitate efficient translation of cellular therapies. These analyses are particularly important for mesenchymal stem/stromal cell (MSC) products. The exquisite responsiveness of MSCs, which makes them attractive candidates for immunotherapies, is a double-edged sword; MSC clinical trials result in inconsistent outcomes that may correlate with underlying patient biology or procedural differences at trial sites. Here we review 45 North American MSC clinical trial results published between 2015 and 2021 to assess whether these reports provide sufficient information for retrospective analysis. Trial reports routinely specify the MSC tissue source, autologous or allogeneic origin and administration route. However, most methodological aspects related to cell preparation and handling immediately prior to administration are under-reported. Clinical trial reports inconsistently provide information about cryopreservation media composition, delivery vehicle, post-thaw time and storage until administration, duration of infusion, and pre-administration viability or potency assessments. In addition, there appears to be significant variability in how cell products are formulated, handled or assessed between trials. The apparent gaps in reporting, combined with high process variability, are not sufficient for retrospective analyses that could potentially identify optimal cell preparation and handling protocols that correlate with successful intra- and inter-trial outcomes. The substantial preclinical data demonstrating that cell handling affects MSC potency highlights the need for more comprehensive clinical trial reporting of MSC conditions from expansion through delivery to support development of globally standardized protocols to efficiently advance MSCs as commercial products.

show abstract